Metal fume fever: characterization of clinical and plasma IL-6 responses in controlled human exposures to zinc oxide fume at and below the threshold limit value.
Results from animal and preliminary human exposure studies have called into question whether the 5 mg/m3 8-hour time-weighted average threshold limit value (TLV) for zinc oxide fume is sufficient to protect workers against metal fume fever. The objectives of this study were to determine the clinical effects of exposures to low concentrations of zinc oxide and to ascertain whether these exposures elevated circulating levels of specific cytokines, which could account for the symptoms of the metal fume fever syndrome. Thirteen resting naive subjects inhaled, on separate days, air and 2.5 and 5 mg/m3 of furnace-generated zinc oxide fume for 2 hours. Subjects recorded symptoms and temperature and had blood drawn before and after each exposure. The mean (+/- SE) maximum rise in oral temperature at 6 to 12 hours after exposure was 1.4 +/- 0.3 degrees F after 5 mg/m3, compared with 0.6 +/- 0.5 degrees F after air exposure (P < 0.05). Mean temperature was also elevated after exposure to 2.5 mg/m3 zinc oxide (1.2 +/- 0.3 degrees F). In a parallel fashion, plasma levels of interleukin 6 (IL-6), a pyrogen, were significantly elevated after exposure to 5 mg/m3 zinc oxide. Mean IL-6 values (pg/mL) at pre-exposure and at 3 and 6 hours post-exposure were 1.9 (+/- 0.6), 2.8 (+/- 0.7), and 2.9 (+/- 0.6), respectively, on the air day and 1.6 (+/- 0.6), 4.4 (+/- 1.2), and 6.4 (+/- 1.1) on the 5 mg/m3 zinc oxide day. Zinc oxide exposure did not significantly affect plasma levels of tumor necrosis factor. Total symptom scores peaked 9 hours after the 5 mg/m3 zinc oxide exposure. Myalgias, cough, and fatigue were the predominant symptoms reported. Inhalation of zinc oxide for 2 hours at the current TLV of 5 mg/m3 produces fever and symptoms along with elevation in plasma IL-6 levels.
Fine
J M
JM
Pulmonary and Critical Care Section, Norwalk Hospital, Conn. 06856, USA.
Gordon
T
T
Chen
L C
LC
Kinney
P
P
Falcone
G
G
Beckett
W S
WS
D000328:Adult; D000336:Aerosols / Q000009:adverse effects; D005260:Female; D005334:Fever / Q000097:blood* / Q000139:chemically induced; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008171:Lung Diseases / Q000097:blood* / Q000139:chemically induced; D008297:Male; D008452:Maximum Allowable Concentration; D009784:Occupational Diseases / Q000097:blood* / Q000139:chemically induced; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*; D015034:Zinc Oxide / Q000009:adverse effects*
D000336:Aerosols; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D015034:Zinc Oxide